Clinical Trial Results: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies [Phase 3]

View source ↗

Summary

Phase 3 expanded access trial results for omidubicel in allogeneic transplantation for hematological malignancies have been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Drugs mentioned

• Omidubicel

Snippet

Sponsor: Gamida Cell ltd | Conditions: Hematological Malignancies | Phase 3 | Status: COMPLETED | Results posted: 2026-06-22